网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
原发性肝细胞癌患者TACE治疗前后血清血管生成素-2水平的变化及其临床意义
作者:张小宾1  冯晓萍2  孙邱3 
单位:1. 宝鸡市人民医院 肝胆脾胰外科, 陕西 宝鸡 721000;
2. 天水市第三人民医院 药械科, 甘肃 天水 741000;
3. 宝鸡市人民医院 介入科, 陕西 宝鸡 721000
关键词:血管生成素-2 经皮肝动脉化疗栓塞 肝细胞癌 
分类号:R735.7
出版年·卷·期(页码):2019·47·第四期(389-393)
摘要:

目的:探讨血管生成素-2(Ang-2)基因多态性与经皮肝动脉化疗栓塞(TACE)治疗肝细胞癌(HCC)患者预后的关系。方法:收集2016年1月至2017年10月于宝鸡市人民医院行TACE治疗的202例HCC患者的临床资料,另选取100例健康体检者作为对照组,采用酶联免疫吸附试验法(ELISA)检测血清Ang-2水平,比较TACE治疗前、后血清Ang-2水平,探讨血清Ang-2水平与临床特征的关系,绘制受试者工作特征曲线(ROC曲线)以评价TACE治疗前、后Ang-2水平判断TACE疗效的效能。结果:HCC患者术前及术后1 d、1周、1个月血清Ang-2水平中位数依次为1 842.7及1 901.8、2 695.3、1 887.7 pg·ml-1,均明显高于对照组的1 040.3 pg·ml-1(均P<0.01)。术后1周血清Ang-2水平较术前显著升高(P<0.01)。术前血清Ang-2水平与BCLC分级、肿瘤数目及肿瘤大小相关。TACE术前和术后1周Ang-2评估术后近期疗效的ROC曲线下面积(AUC)分别是0.902和0.919。Logistic多因素分析结果显示术后1周血清Ang-2水平是影响TACE术后近期预后的独立危险因素(OR=2.611,95%CI为1.258~3.366,P<0.001)。结论:血清Ang-2水平与HCC患者TACE术后近期预后密切相关。

参考文献:

[1] LEE H S,KIM J S,CHOI I J,et al.The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction[J].Cancer,2015,79(11):2087-2094.
[2] ZHAO H,LIU F,YUE Z,et al.Association of hepatic vein lipiodol tram-track sign during transcatheter arterial chemoembolization with perioperative death[J].J Int Med Res,2017,45(3):1148-1157.
[3] ADACHI E,MATSUMATA T,NISHIZAKI T,et al.Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma.The relationship between postoperative course and tumor necrosis[J].Cancer,2015,72(12):3593-3598.
[4] LE C T,LAIDLAW G,MOREHOUSE C A,et al.Synergistic actions of blocking angiopoietin-2 and tumor necrosis factor-α in suppressing remodeling of blood vessels and lymphatics in airway inflammation[J].Am J Pathol,2015,185(11):2949-2968.
[5] LI C,LI Q,CAI Y,et al.Overexpression of angiopoietin 2 promotes the formation of oral squamous cell carcinoma by increasing epithelial-mesenchymal transition-induced angiogenesis[J].Cancer Gene Ther,2016,23(9):295-302.
[6] FANG J H,ZHOU H C,ZHANG C,et al.A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an EMT-independent manner[J].Hepatology,2015,62(2):452-465.
[7] VINCENZI B,MAIO M D,SILLETTA M,et al.Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies:a literature-based meta-analysis[J].PLoS One,2015,10(7):e0133488.
[8] GUAN Q,GU J,ZHANG H,et al.Correlation between vascular endothelial growth factor levels and prognosis of hepatocellular carcinoma patients receiving radiofrequency ablation[J].Biotechnol Biotechnol Equip,2015,29(1):119-123.
[9] ZHANG W,KIM R,QUINTINI C,et al.Prognostic role of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma undergoing liver transplantation[J].Liver Transpl,2015,21(1):101-111.
[10] CHEN J,LAI L,LIU S,et al.Targeting HIF-1α and VEGF by lentivirus-mediated RNA interference reduces liver tumor cells migration and invasion under hypoxic conditions[J].Neoplasma,2016,63(6):934-940.
[11] HE F F,LI H Q,HUANG Q X,et al.Tumor necrosis factor-alpha and 8-hydroxy-2'-deoxyguanosine are associated with elevated urinary angiopoietin-2 level in type 2 diabetic patients with albuminuria[J].Kidney Blood Press Res,2015,40(4):355-365.
[12] 孙慧婷,周怀君,胡娅莉,等.奥沙利铂对子宫内膜癌裸鼠移植瘤生长及促血管生成素-2的影响[J].东南大学学报(医学版),2011,30(3):464-468.
[13] WANG F,DONG X,XIU P,et al.T7 peptide inhibits angiogenesis via downregulation of angiopoietin-2 and autophagy[J].Onco Rep,2015,33(2):675-684.
[14] HSIEH M Y,LIN Z Y,CHUANG W L.Serial serum VEGF-A,angiopoietin-2,and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization[J].Kaohsiung J Med Sci,2011,27(8):314-322.
[15] RONALD J,NIXON A B,MARIN D,et al.Pilot evaluation of angiogenesis signaling factor response after transcatheter arterial embolization for hepatocellular carcinoma[J].Radiology,2017,285(1):311-318.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 284414 位访问者


 ©《现代医学》编辑部
联系电话:025-83272481;83272479
电子邮件: xdyx@pub.seu.edu.cn

苏ICP备09058541